

ELCC 2024 Industry Satellite Symposium

TROP-2–Targeted ADCs for NSCLC: Integrating a New Therapeutic Option

Be at the forefront of lung cancer care!

Interact with experts to discuss the benefits and nuances of incorporating TROP-2–targeted ADCs into treatment plans for advanced NSCLC.

Wednesday, 20 March 2024 | 18:15-19:45 (CET)

South Hall 2, Prague Congress Centre
Prague, Czech Republic



PROGRAM DIRECTOR
DAVID PLANCHARD, MD, PHD
Institut Gustave Roussy
Villejuif, France



LUIS PAZ-ARES, MD, PHD
University Hospital Doce de Octubre
Madrid, Spain



HELENA A. YU, MD
Memorial Sloan Kettering Cancer Center
New York, New York

Agenda

- Welcome and Introduction
- Role of TROP-2 in NSCLC
- Latest Therapeutic Advancements in Targeting TROP-2 in NSCLC
- Contemplating the Future Role of Targeting TROP-2 in NSCLC
- Audience Question and Answer Session

Provided by Clinical Care Options, LLC.

Supported by an educational grant from Gilead Sciences, Inc.



powered by cea